Disorder of Glyoxylate Metabolism disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: DSR052 MIFTS: 28	Disorder of Glyoxylate Metabolism Categories: Endocrine diseases, Metabolic diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Disorder of Glyoxylate Metabolism

MalaCards integrated aliases for Disorder of Glyoxylate Metabolism:

Name: Disorder of Glyoxylate Metabolism ⁵⁸

Hyperoxaluria ³³

Classifications:

MalaCards categories:
Global: Metabolic diseases Rare diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Endocrine, nutritional or metabolic diseases

Metabolic disorders

Inborn errors of metabolism

Inborn errors of carbohydrate metabolism

Disorders of glyoxylate metabolism

Disorders of glyoxylate metabolism, unspecified

Other specified disorders of glyoxylate metabolism

Orphanet: ⁵⁸

Inborn errors of metabolism

External Ids:

Orphanet ⁵⁸ ORPHA308998

ICD11 ³³ 1800430868 1800430868/other 1800430868/unspecified

Sources

Summaries for Disorder of Glyoxylate Metabolism

MalaCards based summary: Disorder of Glyoxylate Metabolism, also known as hyperoxaluria, is related to hyperoxaluria, primary, type i and hyperoxaluria, primary, type ii. The drugs Dapagliflozin and Hydrochlorothiazide have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and bone marrow.

Sources

Related Diseases for Disorder of Glyoxylate Metabolism

Diseases related to Disorder of Glyoxylate Metabolism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 249)

#	Related Disease	Score
1	hyperoxaluria, primary, type i	11.8
2	hyperoxaluria, primary, type ii	11.8
3	hyperoxaluria, primary, type iii	11.4
4	nephrolithiasis, calcium oxalate	11.3
5	primary hyperoxaluria	11.2
6	crystal arthropathies	10.9
7	nephrocalcinosis	10.9
8	nephrolithiasis	10.9
9	end stage renal disease	10.9
10	urolithiasis	10.8
11	kidney disease	10.6
12	chronic kidney disease	10.6
13	abdominal obesity-metabolic syndrome 1	10.4
14	urinary tract infection	10.4
15	acute kidney failure	10.3
16	inherited metabolic disorder	10.3
17	bone disease	10.2
18	hypoascorbemia	10.2
19	hyperparathyroidism	10.2
20	leptin deficiency or dysfunction	10.2
21	metabolic acidosis	10.2
22	leptin receptor deficiency	10.2
23	renal tubular acidosis	10.2
24	renal osteodystrophy	10.1
25	intestinal disease	10.1
26	gastrointestinal system disease	10.1
27	crohn's disease	10.1
28	uremia	10.1
29	distal renal tubular acidosis	10.1
30	idiopathic hypercalciuria	10.1
31	pancreatitis, hereditary	10.1
32	bietti crystalline corneoretinal dystrophy	10.1
33	celiac disease 1	10.1
34	aplastic anemia	10.1
35	inflammatory bowel disease	10.1
36	short bowel syndrome	10.1
37	rickets	10.1
38	pancytopenia	10.1
39	secondary hyperparathyroidism	10.1
40	acute kidney tubular necrosis	10.1
41	liver disease	10.1
42	urinary tract obstruction	10.1
43	neuropathy	10.1
44	peroxisomal disease	10.1
45	bowel dysfunction	10.1
46	down syndrome	10.0
47	inflammatory bowel disease 1	10.0
48	urinary tract infections, recurrent	10.0
49	pyelonephritis	10.0
50	diarrhea	10.0

Graphical network of the top 20 diseases related to Disorder of Glyoxylate Metabolism:

Sources

Symptoms & Phenotypes for Disorder of Glyoxylate Metabolism

Sources

Drugs & Therapeutics for Disorder of Glyoxylate Metabolism

Drugs for Disorder of Glyoxylate Metabolism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dapagliflozin

Approved

Phase 4

461432-26-8

9887712

Hydrochlorothiazide

Approved, Vet_approved

Phase 4

58-93-5

3639

Antihypertensive Agents

Phase 4

Sodium-Glucose Transporter 2 Inhibitors

Phase 4

Hypoglycemic Agents

Phase 4

Sodium Chloride Symporter Inhibitors

Phase 4

diuretics

Phase 4

Lumasiran

Approved, Investigational

Phase 3

1834610-13-7

Pharmaceutical Solutions

Phase 3

Stiripentol

Approved

Phase 2

49763-96-4

5311454

N,N,N-trimethylglycinium

Approved, Experimental, Investigational, Nutraceutical

Phase 2

6915-17-9, 107-43-7

248

Pyridoxine

Approved, Investigational, Nutraceutical, Vet_approved

Phase 2

65-23-6

1054

Pyridoxal phosphate

Approved, Investigational, Nutraceutical

Phase 2

54-47-7

1051

Anticonvulsants

Phase 2

Antimetabolites

Phase 2

Hypolipidemic Agents

Phase 2

Lipid Regulating Agents

Phase 2

Gastrointestinal Agents

Phase 2

Vitamin B6

Phase 2

Vitamin B 6

Phase 2

Brewer's Yeast

Phase 1, Phase 2

Acidophilus

Phase 1, Phase 2

Pyridoxal

Experimental, Nutraceutical

Phase 2

66-72-8

1050

D-Leucine

Experimental, Investigational, Nutraceutical

Phase 1, Phase 2

328-38-1, 61-90-5

439524 6106

Benzocaine

Approved, Investigational

Phase 1

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 1

1401-55-4

16129878 16129778

Liver Extracts

Phase 1

Bilberry

Approved, Experimental

Turmeric

Approved, Experimental, Investigational

Cinnamon

Approved

Cranberry

Approved, Investigational

Milk thistle

Approved, Experimental, Investigational

65666-07-1

Ascorbic acid

Approved, Nutraceutical

50-81-7

54676860 54670067 5785

Aloe

Turmeric extract

Tea

Interventional clinical trials:

(show top 50) (show all 59)

#	Name	Status	NCT ID	Phase	Drugs
1	Dapagliflozin and Hydrochlorothiazide Treatment in Recurring Kidney Stone Patients - a Randomised Single Center Cross-over Study	Not yet recruiting	NCT05443932	Phase 4	Dapagliflozin;Hydrochlorothiazide
2	A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, International Study to Evaluate the Efficacy and Safety of OxabactTM to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria	Completed	NCT00638703	Phase 2, Phase 3	Placebo
3	A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of OxabactTM to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria.	Completed	NCT01037231	Phase 2, Phase 3	Placebo
4	A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria	Completed	NCT03116685	Phase 3
5	Evaluate the Safety and Efficacy of ALLN-177 in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study	Completed	NCT03456830	Phase 3	ALLN-177;Placebo
6	Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis: a Short-term, Prospective, Open-label, Efficacy and Safety Clinical Trial	Recruiting	NCT03346369	Phase 3	Lanthanum Carbonate
7	ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1)	Active, not recruiting	NCT04152200	Phase 3	Lumasiran
8	ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1	Active, not recruiting	NCT03905694	Phase 3	Lumasiran
9	ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1	Active, not recruiting	NCT03681184	Phase 3	Placebo;Lumasiran
10	An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria	Enrolling by invitation	NCT04042402	Phase 3	DCR-PHXC
11	Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)	Terminated	NCT03847090	Phase 3	Reloxaliase;Placebo
12	An Open-label Single-arm Treatment Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact for Patients With Primary Hyperoxaluria Who Completed Study OC5-DB-02	Terminated	NCT03938272	Phase 3
13	Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria	Withdrawn	NCT00280215	Phase 3	ACEI / Angiotensin converting enzyme inhibitor;ARB /Angiotensin Receptor Blocker;Placebo
14	A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of ALLN-177 Treatment Over 28 Days in Patients With Secondary Hyperoxaluria and Kidney Stones	Completed	NCT02547805	Phase 2	ALLN-177;Placebo
15	A Phase 2b, Multi-center, Randomized, Double Blind, Placebo-controlled, Crossover Study to Evaluate Multiple Doses of ALLN-177 in Recurrent Calcium Oxalate Kidney Stone Formers With Hyperoxaluria	Completed	NCT02503345	Phase 2	ALLN-177 low dose;ALLN-177 mid dose;ALLN-177 high dose;Placebo
16	A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria	Completed	NCT03847909	Phase 2	DCR-PHXC;Sterile Normal Saline (0.9% NaCl)
17	Pilot Study of ALLN-177 in Adult and Pediatric Subjects Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia	Completed	NCT03391804	Phase 2	ALLN-177
18	A Phase 2 Multicenter, Open Label, Single Arm Study Evaluating the Effect of ALLN-177 to Reduce Urinary Oxalate Excretion in Recurrent Calcium Oxalate Kidney Stone Formers With Hyperoxaluria	Completed	NCT02289755	Phase 2	ALLN-177
19	A Phase 1/2, Single-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of Subcutaneously Administered ALN-GO1 in Healthy Adult Subjects, and Patients With Primary Hyperoxaluria Type 1	Completed	NCT02706886	Phase 1, Phase 2	Lumasiran;Placebo
20	A Phase 2 Open-label Multi-centre Study to Evaluate the Efficacy and Safety of Oxabact® to Reduce Plasma Oxalate in Subjects With Primary Hyperoxaluria Who Are on Dialysis	Completed	NCT02000219	Phase 2
21	Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria	Completed	NCT03819647	Phase 2	stiripentol (Diacomit)
22	A Phase 1/2, Randomised, Placebo-controlled, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of OC5 to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria	Completed	NCT02012985	Phase 1, Phase 2	Placebo capsules
23	A Pilot Study to Evaluate the Safety and Efficacy of Oxazyme (OC4) in Patients With Hyperoxaluria	Completed	NCT01127087	Phase 1, Phase 2	Oxazyme
24	Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria	Completed	NCT00283387	Phase 2	Betaine;Placebo
25	PILOTSTUDIE ZUR PYRIDOXALPHOSPHATTHERAPIE BEI PATIENTEN MIT PRIMÄRER HYPEROXALURIE TYP I (PHOX-B6-PILOT) Pilot Trial on Treatment of Patients With Primary Hyperoxaluria Type I With Pyridoxal-phosphate	Completed	NCT01281878	Phase 2	Vitamin B 6
26	Influence of Hydroxyproline Plasma Concentration on Its Metabolism to Oxalate	Completed	NCT02038543	Phase 1, Phase 2	Hydroxyproline and Leucine
27	Use of Oral Probiotics to Reduce Urinary Oxalate Excretion	Completed	NCT00587041	Phase 1, Phase 2
28	A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients From Birth to 11Years of Age With Primary Hyperoxaluria and Relatively Intact Renal Function	Recruiting	NCT05001269	Phase 2	nedosiran
29	A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without Dialysis	Recruiting	NCT04580420	Phase 2	DCR-PHXC
30	Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria	Recruiting	NCT04909723	Phase 1, Phase 2	NB2000P;Placebo
31	A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients With Primary Hyperoxaluria Type 1	Active, not recruiting	NCT03350451	Phase 2	Lumasiran
32	Effects of Pyridoxamine on Oxalate Excretion in Stone Disease and Hyperoxaluria	Withdrawn	NCT00490113	Phase 2	Pyridoxamine
33	Investigations Into the Genotype and Phenotype of Unclassified Hyperoxaluria: Enteric Oxalate Absorption Study	Completed	NCT00588120	Phase 1	C-13 labeled oxalate
34	A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients With Primary Hyperoxaluria Type 3	Completed	NCT04555486	Phase 1	DCR-PHXC;Sterile Normal Saline (0.9% NaCl)
35	A Placebo-Controlled, Single-Blind, Single-Center Phase 1 Study in Normal Healthy Volunteers and Open-Label Multi-Center Study in Patients With Primary Hyperoxaluria to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DCR-PHXC Solution for Injection (Subcutaneous Use)	Completed	NCT03392896	Phase 1	DCR-PHXC;Placebo
36	A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB8802 in Healthy Volunteers and in Patients With Enteric Hyperoxaluria	Recruiting	NCT04629170	Phase 1	SYNB8802;Placebo
37	A Phase 1 Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)	Terminated	NCT02795325	Phase 1	DCR-PH1
38	Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric Patients	Unknown status	NCT02794649
39	Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1	Approved for marketing	NCT04125472		Lumasiran
40	A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria	Completed	NCT03095885
41	"Pilot Study: Proteomics of Primary Hyperoxaluria Type 1 (PH1): A Rare Calcium Oxalate Stone Disease"	Completed	NCT03067142
42	Correlation of Disease Expression With Specific Genetic Mutations in Primary Hyperoxaluria	Completed	NCT00589225
43	Genetic Characterization and Genotype/Phenotype Correlations in Primary Hyperoxaluria	Completed	NCT02340689
44	IDENTIFICATION OF A MULTI-ANALYTE PROFILE FOR PRIMARY HYPEROXALURIA AND COMPARISON WITH HEALTHY SIBLINGS AND IDIOPATHIC HYPERCALCIURIA	Completed	NCT02830009
45	Assessment of Health-related Quality of Life in Rare Kidney Stone Formers in the Rare Kidney Stone Consortium	Completed	NCT02124395
46	Determination of Reference Interval of Spot Urinary Oxalate to Creatinine Ratio in Children of Pakistani Origin Under Six Years of Age	Completed	NCT04756024
47	Plasma Oxalate in Patient With Short Bowel	Completed	NCT04119765
48	Relationship of Spot Urine Oxalate to Creatinine Ratio and 24 Hours Urinary Oxalate Excretion in Patients With Urolithiasis	Completed	NCT04571359
49	Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk	Completed	NCT02404701
50	Urinary Proteomic Profiling Using ProteinChip SELDI-TOF-MS: A Potential Means of Identifying Protein Biomarkers of Urinary Stone Formers	Completed	NCT00199459

Search NIH Clinical Center for Disorder of Glyoxylate Metabolism

Sources

Genetic Tests for Disorder of Glyoxylate Metabolism

Sources

Anatomical Context for Disorder of Glyoxylate Metabolism

Organs/tissues related to Disorder of Glyoxylate Metabolism:

MalaCards : Kidney, Liver, Bone Marrow, Small Intestine, Bone, Spinal Cord, Colon

Sources

Publications for Disorder of Glyoxylate Metabolism

Articles related to Disorder of Glyoxylate Metabolism:

(show top 50) (show all 2715)

#	Title	Authors	PMID	Year
1	Preemptive liver transplant in two patients with primary hyperoxaluria type 1: Clinical significance of nephrolithiasis and nephrocalcinosis. ⁶²	Uchida H...Kasahara M	35979862	2022
2	Metabolic and Genetic Evaluation in Children with Nephrolithiasis. ⁶²	Mandal A...Bagga A	35819704	2022
3	A pilot dynamic analysis of formative factors of nephrolithiasis related to metabolic syndrome: evidence in a rat model. ⁶²	He Q...Gupta S	35837686	2022
4	Cutaneous Oxalosis Due to Primary Hyperoxaluria. ⁶²	Ly S...Shalin S	36395453	2022
5	Increased Rates of Supplement-Associated Oxalate Nephropathy During COVID-19 Pandemic. ⁶²	Fong P...Andeen NK	36120391	2022
6	Three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I. ⁶²	Merz LM...Hoppe B	36472654	2022
7	Lactate dehydrogenase A inhibitors with a 2,8-dioxabicyclo[3.3.1]nonane scaffold: A contribution to molecular therapies for primary hyperoxalurias. ⁶²	Alejo-Armijo A...Salido S	36113265	2022
8	Chitosan derivatives as nanocarriers for hLDHA inhibitors delivery to hepatic cells: A selective strategy for targeting primary hyperoxaluria diseases. ⁶²	Salido S...Altarejos J	36181922	2022
9	Secondary oxalate nephropathy and kidney transplantation. ⁶²	Aziz F...Garg N	36342385	2022
10	Clinical exome sequencing uncovers an unsuspected diagnosis of Bartter syndrome type 2 in a child with incidentally detected nephrocalcinosis. ⁶²	Saha A...Patel H	35195872	2022
11	Long-term outcomes after pre-emptive liver transplantation in primary hyperoxaluria type 1. ⁶²	Shasha-Lavsky H...Weissman I	36449101	2022
12	Searching glycolate oxidase inhibitors based on QSAR, molecular docking, and molecular dynamic simulation approaches. ⁶²	Cabrera N...Contreras-Torres E	36402831	2022
13	Dominant negative mutation in oxalate transporter SLC26A6 associated with enteric hyperoxaluria and nephrolithiasis. ⁶²	Corniere N...Eladari D	35115415	2022
14	Etiology, urine metabolic risk factors, and urine oxalate patterns in patients with significant hyperoxaluria and recurrent nephrolithiasis. ⁶²	Moore JP...Keddis MT	35917078	2022
15	Pediatric urolithiasis: what can pediatricians expect from radiologists? ⁶²	Bernardor J...Cabet S	36329164	2022
16	Oxalate homeostasis. ⁶²	Ermer T...Knauf F	36329260	2022
17	Clinical and molecular characterization of a large primary hyperoxaluria cohort from Saudi Arabia: a retrospective study. ⁶²	Alfadhel M...Alhasan KA	36409364	2022
18	CRISPR/Cas9-mediated knock-out of AGXT1 in HepG2 cells as a new in vitro model of Primary Hyperoxaluria Type 1. ⁶²	Gatticchi L...Cellini B	35964771	2022
19	Nedosiran, a Candidate siRNA Drug for the Treatment of Primary Hyperoxaluria: Design, Development, and Clinical Studies. ⁶²	Liu A...Zhong XB	36407951	2022
20	What treatments reduce kidney stone risk in patients with bowel disease? ⁶²	Bianco J...Prochaska M	35976425	2022
21	Analysis and Characterization of Lactobacillus paragasseri and Lacticaseibacillus paracasei: Two Probiotic Bacteria that Can Degrade Intestinal Oxalate in Hyperoxaluric Rats. ⁶²	Mehra Y...Viswanathan P	35699895	2022
22	Diagnostic Code-Based Screening for Identifying Children with Primary Hyperoxaluria. ⁶²	Tasian G...Ching C	35930731	2022
23	Retraction: Molecular Diagnosis of Primary Hyperoxaluria Type 1 and Distal Renal Tubular Acidosis in Moroccan Patients With Nephrolithiasis and/or Nephrocalcinosis. ⁶²	Fatima A...Karim O	36246090	2022
24	Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of 5 cases. ⁶²	Sellier-Leclerc AL...Bacchetta J	36307929	2022
25	The retinal phenotype in primary hyperoxaluria type 2 and 3. ⁶²	Birtel J...Charbel Issa P	36260161	2022
26	Small interfering RNA: Discovery, pharmacology and clinical development-An introductory review. ⁶²	Ranasinghe P...Webb DJ	36250252	2022
27	Chronic liver disease and hepatic calcium-oxalate deposition in patients with primary hyperoxaluria type I. ⁶²	Recker P...Hoppe B	36202824	2022
28	A case report of invasive infantile primary hyperoxaluria type 1 and literature review. ⁶²	Ni T...Zhao F	36194362	2022
29	HOGA1 gene pathogenic variants in primary hyperoxaluria type III: Spectrum of pathogenic sequence variants, and phenotypic association. ⁶²	Abid A...Khaliq S	36259736	2022
30	Primary hyperoxaluria: Comprehensive mutation screening of the disease causing genes and spectrum of disease-associated pathogenic variants. ⁶²	Abid A...Rizvi SA	36185032	2022
31	Clinical and molecular characterization of primary hyperoxaluria in Egypt. ⁶²	Soliman NA...Milliner DS	36151119	2022
32	Primary Hyperoxaluria: A Need for New Perspectives in an Era of New Therapies. ⁶²	Somers MJG	36184293	2022
33	4-PBA rescues hyperoxaluria induced nephrolithiasis by modulating urinary glycoproteins: Cross talk between endoplasmic reticulum, calcium homeostasis and mitochondria. ⁶²	Bhardwaj R...Kaur T	35809664	2022
34	A Friend or a Foe? Bariatric Surgery in Chronic Kidney Disease: A Case Report. ⁶²	Bagai S...Khullar D	36465578	2022
35	Estimated GFR Slope Across CKD Stages in Primary Hyperoxaluria Type 1. ⁶²	Singh P...Lieske JC	35306035	2022
36	Therapeutic siRNA: State-of-the-Art and Future Perspectives. ⁶²	Friedrich M...Aigner A	35997897	2022
37	Postbiotics and Kidney Disease. ⁶²	Favero C...Sanchez-Nino MD	36136562	2022
38	Probiotic Oxalate-Degrading Bacteria: New Insight of Environmental Variables and Expression of the oxc and frc Genes on Oxalate Degradation Activity. ⁶²	Karamad D...Miller AW	36141002	2022
39	Nephro-protective effect of Daphnetin in hyperoxaluria-induced rat renal injury via alterations of the gut microbiota. ⁶²	Zhou R...Zhang W	35994414	2022
40	Whole-exome sequencing and variant spectrum in children with suspected inherited renal tubular disorder: the East India Tubulopathy Gene Study. ⁶²	Sinha R...Mandal K	35006361	2022
41	Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial. ⁶²	Hayes W...Frishberg Y	35913563	2022
42	Primary hyperoxaluria and genetic linkages: an insight into the disease burden from Pakistan. ⁶²	Hashmi S...Zafar MN	35678848	2022
43	Next-generation sequencing in identification of pathogenic variants in primary hyperoxaluria among 21 Egyptian families: Identification of two novel AGXT gene mutations. ⁶²	Ahmed HA...Amr K	35661454	2022
44	Lessons for the clinical nephrologist: lumasiran as the future cornerstone treatment for patients with primary hyperoxaluria type 1? ⁶²	Gillion V...Godefroid N	35986861	2022
45	PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. ⁶²	Baum MA...PHYOX2 study investigators	36007597	2022
46	The appearance of oxalate crystals in a kidney biopsy is no proof of post-transplant oxalate nephropathy in primary hyperoxaluria type 1. ⁶²	Metry EL...Bacchetta J	35870818	2022
47	Improved Outcome of Infantile Oxalosis Over Time in Europe: Data From the OxalEurope Registry. ⁶²	Deesker LJ...Bacchetta J	35812297	2022
48	Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial. ⁶²	Michael M...Magen D	35843439	2022
49	Progress with RNA Interference for the Treatment of Primary Hyperoxaluria. ⁶²	Sawyer K...Wood KD	35731461	2022
50	Primary hyperoxaluria type 1: report of the worldwide largest family. ⁶²	Agrebi I...Hmida MB	34796413	2022